Search
Filter Results
Displaying 581–590 of 749 for “retinal diseases”
-
Oct 23, 2026
Emerging gene therapy for RDH12-associated Leber congenital amaurosis cleared for clinical trials
Research NewsFDA clears investigational new drug application for OPGx-RDH12 from Opus Genetics
-
Oct 12, 2026
Beacon StoriesMaggie grew up watching her mom navigate retinitis pigmentosa (RP), shaping her understanding of how vision loss affects entire families. Today, she uses her voice to raise awareness, support research, and help others affected by blinding diseases feel less alone.
-
At Scramble for Sight, every round has a greater purpose. Set against the backdrop of some of the nation’s most sought-after golf courses, these premier events blend exceptional play, elevated hospitality, and meaningful engagement with the mission of the Foundation Fighting Blindness.
-
The Foundation Fighting Blindness’ signature golf and gala events are elevated experiences that combine world-class hospitality with powerful purpose.
-
Every voice strengthens our movement. By joining our advocacy network, you’ll receive updates on the latest policy developments, alerts when action is needed, and stories of impact from advocates nationwide. Together, we can shape policies that accelerate treatment and cures, and improve the lives of millions living with blinding diseases.
-
Sep 22, 2026
Beacon's emerging XLRP gene therapy improves low-light vision in phase 3 trial
Research NewsBeacon plans to begin a rolling FDA submission for laru-zova later this year
-
Sep 15, 2026
Leber Congenital Amaurosis Research Advances
Research NewsRecent developments in research on Leber congenital amaurosis.
-
Aug 24, 2026
Tarsus plans to purchase Alkeus, developer of emerging Stargardt treatment
Research NewsDeal marks another step as gildeuretinol advances towards patients
-
Jul 1, 2026
Eye on the Cure Podcast | Episode 101: Dr. Patrick Staropoli
Eye on the CureNew host Maddie Mossman interviews retinal surgeon Dr. Staropoli, the first medical doctor to win a NASCAR race.
-
Apr 21, 2026
Atsena Therapeutics Advances to Pivotal Phase 3 Trial for X-Linked Retinoschisis
Research NewsData monitoring committee recommends proceeding with registration-enabling study for ATSN-201